Axol Bioscience (Axol), a biotechnology company specializing in the use of stem cell technology to manufacture disease-relevant cell-based assay systems to the drug discovery industry, today announced ...
CAMBRIDGE, England & EDINBURGH, Scotland--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, ...
Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive ...
Axol Bioscience’s CiPA-validated ventricular cardiomyocytes can be used as a robust cardiotoxicity measurement tool. Axol Bioscience, a provider of induced pluripotent stem cell (ISPC)-derived cells, ...
The relationship brings together Horizon’s precision genome editing capability and Axol’s expertise in iPSC reprogramming and differentiation to provide isogenic cell lines for neuronal and ...
Sygnature Discovery, a world-leading integrated drug discovery provider and non-clinical solutions provider, has announced a scientific collaboration with human induced pluripotent stem cell (iPSC) ...
Axol Bioscience and Censo Biotechnologies have merged to set up a one-stop-shop for induced pluripotent stem cells (iPSCs). IPSCs are derived from skin or blood cells that have been reprogrammed back ...
Companies will incorporate cells and technology to create a ‘clinical trial in a dish’ Companies will incorporate cells and technology to create a ‘clinical trial in a dish’ Axol Bioscience – a stem ...
CAMBRIDGE, England--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback